1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Historic Inter-Korean Summit Sparks Hopes Of Healthcare Exchanges

 
• By Jung Won Shin

Following the signing of the Panmunjeom Declaration after their recent historic summit, North and South Korea are poised to resume economic cooperation, including projects in the healthcare sector, in line with an agreement the two sides reached in 2007. Although progress will likely depend on the upcoming summit between the US and North Korea and whether international sanctions are lifted, hopes over direct inter-Korean exchanges are brewing.

South and North Korea
NORTH AND SOUTH KOREA EDGE CLOSER

The historic inter-Korean summit that confirmed the North and South's goal of achieving the denuclearization of the Korean peninsula and officially ending the Korean War, which left the countries technically still in conflict, has also sparked expectations for the resumption of economic cooperation, including in the healthcare industry.

As part of the Panmunjeom Declaration announced by South Korean President Moon Jae-in and North Korean leader Kim Jong Un after the summit on April 27, the two Koreas will actively pursue business projects which had been agreed during the signing of the October 4 declaration in 2007

More from South Korea

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

More from Focus On Asia